Počet záznamů: 1
Quality of Life and Patient Satisfaction inPatients with Atrial Fibrillation on Stable Vitamin K Antagonist Treatment or Switched to a non-Vitamin K Antagonist Oral Anticoagulant during a 1-year follow-up: A PREFER in AF Registry Substudy.
- 1.
SYSNO ASEP 0492389 Druh ASEP J - Článek v odborném periodiku Zařazení RIV Záznam nebyl označen do RIV Poddruh J Článek ve WOS Název Quality of Life and Patient Satisfaction inPatients with Atrial Fibrillation on Stable Vitamin K Antagonist Treatment or Switched to a non-Vitamin K Antagonist Oral Anticoagulant during a 1-year follow-up: A PREFER in AF Registry Substudy. Tvůrce(i) De Caterina, R. (IT)
Brüggenjürgen, B. (DE)
Darius, H. (DE)
Köhler, S. (DE)
Lucerna, M. (DE)
Pecen, Ladislav (UIVT-O) RID, SAI, ORCID
Renda, G. (IT)
Schilling, R. J. (GB)
Schliephacke, T. (DE)
Zamorano, J. (ES)
Le Heuzey, J.Y. (FR)
Kirchhof, P. (GB)Zdroj.dok. Archives of Cardiovascular Diseases. - : Elsevier - ISSN 1875-2136
Roč. 111, č. 2 (2018), s. 74-84Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. FR - Francie Klíč. slova Antagonist oral anticoagulants ; Antivitamine K ; Atrial fibrillation ; Changement de traitement ; Non-vitamin K ; Patient satisfaction ; Quality of life ; Switching ; Vitamin K antagonists UT WOS 000427215600002 EID SCOPUS 85029575240 DOI 10.1016/j.acvd.2017.04.007 Anotace BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are being introduced for stroke prevention in non-valvular Atrial Fibrillation (AF), and promise to be accepted better than Vitamin K Antagonists (VKAs) by patients, improving their Quality of Life (QoL). AIM: To assess to what extent patient-related factors influence decisions to switch from a VKA to a NOAC. METHODS: The PREFER in AF Registry collected data at baseline in 2012 - at the beginning of NOAC prescriptions - and at 1-year follow-up, in 6412 patients in seven Western European countries. QoL and patient satisfaction questionnaires (EQ-5D-5L and/or PACT-Q2) were completed in 3777 patients at both visits. Data were compared across categories of patients on stable treatment with a VKA (i.e. continuously over the previous 12 months) (n=2102) or recently switched (within 12 months) from a VKA to a NOAC (n=213) during a 1-year follow-up, allowing a snapshot of factors influencing the switch at a time when NOACs were being introduced into the market. RESULTS: Compared to patients on stable treatment with a VKA, switched patients were similar in terms of age, sex, body mass index and other risk factors, but had lower prevalences of hypertension and heart valve dysfunction, and a lower rate of use of concomitant treatment with antiplatelet/anti-inflammatory agents; they also had a lower CHA2DS2-VASc score. Among 25 features investigated, switched patients more often reported bruising or bleeding, complained about bruising, were dissatisfied with the anticoagulant treatment, and reported mobility problems and anxiety/depressive traits. CONCLUSIONS: At the beginning of NOAC prescriptions, European doctors tended to switch from VKAs to NOACs those patients at lower risk than "non-switchers". Complaints about bruising or bleeding, dissatisfaction with treatment, mobility problems and anxiety/depression traits appear to be related to - and may have influenced - the choice to switch from a VKA to a NOAC. Pracoviště Ústav informatiky Kontakt Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Rok sběru 2019
Počet záznamů: 1